GOOD READS

HistoGenetics Selects Illumina’s MiSeq® System as Next-Generation Sequencing Platform of Choice

MiSeq Will Supplement HistoGenetics’ Existing Human Leukocyte Antigen Sequence-Based Typing

RELATED QUOTES

SymbolPriceChange
ILMN151.68-2.01

SAN DIEGO & NEW YORK--(BUSINESS WIRE)--

Illumina, Inc. (ILMN) today announced that HistoGenetics, the leader in high-resolution sequence-based human leukocyte antigen (HLA) testing services, has selected the MiSeq sequencing system for use in its CLIA laboratory. HistoGenetics will deploy multiple MiSeqs to supplement its existing Sanger sequencing workflow to sequence HLA genes with high accuracy and speed. In addition to their utility in tissue matching for transplants, HLA gene variations have known associations with a wide variety of autoimmune diseases, infectious diseases, and some cancers.

Despite their importance, HLA genes have not been routinely typed at higher resolution because of the technical challenges of accurately discriminating between these highly related genes and their many alleles. HistoGenetics, one of the largest HLA typing laboratories in the world, has previously implemented Sanger sequencing as the sole method for higher resolution HLA typing. With its deployment of MiSeqs, HistoGenetics will lead the transition from Sanger sequencing to next-generation sequencing for HLA typing.

“We anticipate building on our leadership position and established success by leveraging the MiSeq platform,” said Dr. Nezih Cereb, Chief Executive Officer and Co-founder of HistoGenetics. “Based on our experience with other technologies, we think the MiSeq’s quality data output and simple workflow, combined with Illumina’s commitment to work collaboratively, is the ideal solution to enable us to provide our customers with the superior results and turnaround time they require.”

HistoGenetics currently provides two levels of resolution with HLA sequencing-based testing, including high-level and registry-level resolution. At high resolution, the most comprehensive level, all ambiguities are resolved in the antigen recognition sites, and new and rare alleles missed by other methods typically can be found. The American Society for Histocompatibility and Immunogenetics and the National Marrow Donor Program require this level of testing for stem cell transplants. At the registry level, which is used for unrelated donor registries (such as the Be The Match RegistryTM) and cord blood banks, a majority of ambiguities are resolved.

“By introducing the MiSeq, we will be able to provide gold-level high resolution typing to pre-transplant work-ups, as well as to registry donors, and improve the turnaround time for sample processing,” added Dr. Cereb.

HistoGenetics’ turnaround time for typing services is currently as short as three days for urgent samples. To date, HistoGenetics has typed more than 3 million samples and performed more than 13 million sequence-based typings that led to the discovery of more than 16,000 samples carrying a new variant of an HLA allele.

“Next-generation sequencing has the potential to transform HLA genotyping, and we believe Illumina’s technology is well-positioned to help drive that change,” said Matt Posard, Senior Vice President and General Manager of Illumina's Translational and Consumer Genomics business. “The MiSeq can make a significant difference in terms of accuracy and speed for production-scale HLA typing. We look forward to a successful relationship with HistoGenetics.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

About HistoGenetics, LLC

HistoGenetics (www.histogenetics.com) is the global leader in HLA sequence-based typing (SBT). As a pioneer the field, the company has provided its services for donor registries, donor centers, cord blood typing, transplant centers, HLA laboratories and pharmacogenomics applications. To date, HistoGenetics has performed more than 13 million SBTs and discovered 16,000 samples carrying new alleles. The company was founded by Dr. Soo Young Yang, who serves as Chairman, and Dr. Nezih Cereb, Chief Executive Officer.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

Contact:
Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com

Quiz: How well do you know India's economy?

Question 1

Which of these products is India the world's largest producer of?

Poll Choice Options
  • Wheat
  • Rice
  • Milk
1
2
3
4
5
6
7
8
9
10

Latest News

  • Strides surges as Bangalore plant remains U.S. FDA compliant

    Reuters Market Eye - Strides Arcolab surges 6.3 percent after the drugmaker said on Friday its oral drug manufacturing facility in Bangalore continues to maintain compliance with the manufacturing standards of the U.S. health regulator. "U.S. FDA recently inspected this facility as part of GMP compliance audit and raised Form 483 (inspection observations) during the Dec 2013 inspection (which has now been satisfactorily closed)," Macquarie said in a note to its clients. This is a key positive …

  • French companies to continue investing around $1 bn in India

    New Delhi, April 25 (IANS) Expressing confidence in the Indian economy, French companies that are engaged in India will continue to annually invest nearly $1 billion here as they see long-term future in the country's growth potential, a top diplomat has said. "I expect the investment trend of nearly a billion dollars to continue as the French companies are here for the long-term and are setting up their base here and expanding production," French Ambassador François Richier told IANS in an …

  • `India needs over 26,000 independent directors'

    Kochi, April 25 (IANS) India needs over 26,000 independent directors and around 2,500 women directors to fill the boards of companies across the country, an official said here Friday. Lt. Gen (Retd) J.S. Ahluwalia, president of the Institute of Directors, said that despite a handful of high profile female Indian entrepreneurs, the proportion of female directors is a meagre 5.2 percent, which is even below the developing world percentage of 7.2 percent. Ahluwalia's statement comes at a time …

  • India's growth prospects dim regardless of election outcome - Reuters  …

    Prospects for a strong economic rebound in India are dim as industry remains weak, and although a business-friendly opposition party looks likely to form a new government, its ability to pass sweeping reforms is in doubt, a Reuters poll showed. An anticipated victory for the Bharatiya Janata Party's (BJP) at the conclusion next month of an ongoing election in the world's largest democracy has pushed India's stock market to a record high. Anubhuti Sahay, senior economist at Standard Chartered …

  • World shares, dollar struggle on Ukraine anxiety

    Heightened tension in Ukraine pushed world shares lower and lifted safe-haven European bonds on Friday, taking the shine off what looked set to be an earnings and M&A-driven week of gains for European and U.S. stocks. Trouble in Ukraine escalated after Ukrainian forces killed up to five pro-Russia separatists on Thursday and Russia conducted military drills near the border, raising fears it was gearing up to invade. European shares tumbled 0.5 percent in early trading as concerns also rose …

IN-DEPTH ANALYSIS & INTERVIEWS

  • Too good to be true?

    Developers are offering lucrative buyback schemes. But such promises may not be always kept. …

  • Leaderspeak with Vikram Limaye

    Vikram Limaye MD & CEO, IDFC Ltd shares many firsts from his life. …

  • The Greening of the House of Tatas

    How a dedicated team converted a 90-year-old heritage structure into a benchmark for environment-friendly buildings. …

  • Appy Voting

    Mobile and online apps, seeking to inform or influence voters, have been more active than ever before in this election. …

  • In the crosshairs

    Why the future of FDI in multi-brand retail looks bleak after the polls. …

  • Deserving the honour

    How do the winners of the two new banking licences - microfinance lender Bandhan Financial Services and infra institution IDFC Ltd - measure up to the challenges of operating as full-fledged banks? …

  • A Samurai from Chandigarh

    Advertising veteran Sandeep Goyal is disarmingly frank as he recounts his years with Dentsu. …

MARKET MOVERS

  • Most Actives
    Most Actives
    NamePriceChange% Chg
    23.45-0.40-1.68%
    ASHOKLEY.BO
    16.46-0.06-0.36%
    UNITECH.BO
    128.90+8.50+7.06%
    FRL.BO
    75.85+3.55+4.91%
    HDIL.BO
    116.700.000.00%
    IDFCSL.BO
  • Price % Gainers
    Price % Gainers
    NamePriceChange% Chg
    12.56+2.05+19.51%
    BIBCL.BO
    548.00+82.00+17.60%
    STRIDES.BO
    31.95+4.10+14.72%
    STOREONE.BO
    261.45+31.40+13.65%
    VIVIMEDLABS.BO
    163.20+19.50+13.57%
    AGARIND.BO
  • Price % Losers
    Price % Losers
    NamePriceChange% Chg
    -10.95-100.00%
    4THGEN.BO
    -17.30-100.00%
    ALFAICA.BO
    -17.65-100.00%
    AMAL.BO
    -12.31-100.00%
    BORAX.BO
    -29.95-100.00%
    BRADYM.BO
  •  
    Recent Quotes
    Symbol Price Change % ChgChart 
    Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.
    You need to enable your browser cookies to view your most recent quotes.
  • Recent Quotes News

    •  
      Sign-in to view quotes in your portfolios.